Cytori Patents Adipose-Derived Cell Therapy for Cardiovascular Disease in Australia

Cytori Patents Adipose-Derived Cell Therapy for Cardiovascular Disease in Australia

SAN DIEGO--(BUSINESS WIRE)-- Cytori Therapeutics (NAS: CYTX) has received an Australian patent covering methods of treating cardiovascular disease using adipose-derived regenerative cells (ADRCs). The patent covers the therapeutic use of ADRCs for improving cardiac function and mechanics by preventing the deleterious histopathological and structural changes that occur in the heart following a heart attack (cardiac remodeling).

"This patent expands our growing body of global patents surrounding therapeutic uses for our Celution® cell output," said Christopher Calhoun, CEO of Cytori. "As previously reported, we are encouraged by the positive clinical results in our cardiovascular trials to date and cardiovascular disease remains a core focus of the Company."

The patent is not limited to any particular way of obtaining ADRCs, covering both manual and automated methods of obtaining the cells. This includes the use of a sterile, closed system such as Cytori's proprietary Celution® System. The claims also cover multiple cell populations and cell delivery methods, including intravenous delivery.

Cytori received notice from the Australian Therapeutic Goods Administration (TGA) that the Celution® System was approved for commercial use through inclusion on the Australian Registry of Therapeutic Goods for autologous re-implantation and re-infusion of a patient's own ADRCs in August 2013. This approval enables physicians to treat critical unmet medical needs with point-of-care cell therapies and to conduct important clinical research in promising therapeutic areas.

The patent complements Cytori's existing patents in Australia covering the Celution® System and builds upon the Company's global patent strategy encompassing therapeutic indication-specific, methods and device patents. Cytori now has 64 issued patents and more than 75 active patent applications worldwide.

About Adipose Tissue & ADRCs

Adipose tissue is considered the richest source of regenerative cells in the body. These cells are comprised of a heterogeneous population of cells which are collectively referred to as ADRCs. The heterogeneous nature of ADRCs are believed to contribute to the healing process via multiple mechanisms, which include cell-to-cell signaling, supporting improved blood flow and regulation of the inflammatory response.

About Cytori

Cytori Therapeutics is developing cell therapies based on autologous adipose-derived regenerative cells (ADRCs) to treat cardiovascular disease and other medical conditions. Our scientific data suggest ADRCs improve blood flow, moderate the inflammatory response and keep tissue at risk of dying alive. As a result, we believe these cells can be applied across multiple "ischemic" conditions. These therapies are made available to the physician and patient at the point-of-care by Cytori's proprietary technologies and products, including the Celution® System product family.

Cytori Therapeutics
US Investors
Tom Baker, +1.858.875.5258
Megan McCormick, +1.858.875.5279
Cytori Therapeutics, Australia
David Oxley, +1.858.337.3565

KEYWORDS:   Australia  United States  North America  Australia/Oceania  California


The article Cytori Patents Adipose-Derived Cell Therapy for Cardiovascular Disease in Australia originally appeared on

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story